Acrivon Therapeutics Inc
ACRV
Company Profile
Business description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Contact
480 Arsenal Way
Suite 100
WatertownMA02472
USAT: +1 617 207-8979
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
78
Stocks News & Analysis
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
stocks
After earnings, is Disney stock a buy, a sell, or fairly valued? -
Following the highly anticipated announcement of a new CEO, here’s what we think of Disney.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,139.90 | 34.50 | -0.38% |
| CAC 40 | 8,327.88 | 4.60 | 0.06% |
| DAX 40 | 24,987.85 | 27.02 | -0.11% |
| Dow JONES (US) | 50,188.14 | 52.27 | 0.10% |
| FTSE 100 | 10,353.84 | 32.39 | -0.31% |
| HKSE | 27,183.15 | 155.99 | 0.58% |
| NASDAQ | 23,102.47 | 136.20 | -0.59% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,462.90 | 16.53 | 0.12% |
| S&P 500 | 6,941.81 | 23.01 | -0.33% |
| S&P/ASX 200 | 8,867.40 | 44.20 | -0.50% |
| SSE Composite Index | 4,128.37 | 5.28 | 0.13% |